Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 5/11/23 → 5/10/25 |
Funding
- Merck Sharp & Dohme Corporation: $124,182.00
22-HN-37-MSD (689-07): A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell
- Arnold, Susanne (PI)